Neurocrine Biosciences' INGREZZA® Shows Promising Results for Huntington's Disease Treatment

Neurocrine Biosciences Advances Huntington's Disease Treatment with INGREZZA® Findings

Neurocrine Biosciences, Inc. presents compelling new data from the KINECT®-HD2 study, showcasing the effectiveness of INGREZZA® (valbenazine) in managing chorea associated with Huntington's disease. This research, unveiled at the 2025 MDS International Congress of Parkinson's Disease and Movement Disorders, highlights the drug’s ability to significantly reduce chorea severity over an extended period. In a study involving 154 adult participants, INGREZZA demonstrated early and sustained symptom relief, with a notable mean improvement of -3.4±0.3 in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) score observed just two weeks after initiating treatment at the 40 mg dose. These findings underscore INGREZZA's long-term efficacy, as enhancements continue to be documented through Week 156.

The study also indicates strong patient-reported outcomes, with 34.5% of participants noting improvements on the Patient Global Impression of Change (PGI-C) scale by Week 2. This figure grows significantly to 75.9% by Week 104 and stabilizes at 77.8% by Week 156, indicating a sustained response to treatment. Importantly, the research confirms that concurrent use of antipsychotic medications does not hinder the management of chorea, which is a critical consideration for patients who may require additional psychiatric care. Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine, emphasizes the importance of these findings in providing meaningful management for a condition that severely impacts patients' quality of life.

The overall safety profile of INGREZZA remains consistent with prior studies, with treatment-emergent adverse events (TEAEs) aligning with established expectations for the medication. These results not only reaffirm the drug’s role in improving the lives of individuals with Huntington's disease but also highlight Neurocrine's commitment to addressing complex neurological disorders through innovative therapeutic solutions. The findings from the KINECT-HD2 study position INGREZZA as a key player in the Huntington’s disease treatment landscape, showcasing the potential for sustained symptom relief and enhanced patient outcomes.

In a separate development, Neurocrine Biosciences appoints Mike Sibley as Senior Vice President and General Manager of its Neuropsychiatry franchise, effective October 6, 2025. With over 20 years of experience, Sibley is set to enhance Neurocrine's market strategy, particularly for the INGREZZA franchise, during a pivotal time for the company. His previous roles at major biopharmaceutical firms position him as a strong leader capable of advancing Neurocrine's objectives in the neuropsychiatry domain.

Neurocrine's dedication to developing transformative treatments for neurological disorders continues to drive its innovative pipeline. With a robust portfolio of FDA-approved therapies and ongoing clinical developments, the company remains focused on alleviating the burden of debilitating diseases, offering hope to patients and families affected by these conditions.